Results 51 to 60 of about 12,152 (205)
Clinical applications of mifepristone [PDF]
, 2006 Mifepristone is a progesterone antagonist that has been studied for a number of clinical applications. It is a well-known abortifacient that is effective for both first- and second-trimester medical abortion when used with a prostaglandin analog.
Ho, PC, Tang, OS
core +1 more source
Exploring the Journey of Mifepristone in Canada and Australia [PDF]
, 2020 Mifepristone, also known by its drug development name RU486, is an anti-progestin that is part of the gold standard regimen of medication abortion. This medication is taken orally to induce an abortion through 70 days after the first day of the pregnant ...
LaRoche, Kathryn J.
core +1 more source
F&S ReportsObjective: To describe patterns and variations in the medical and procedural management of early pregnancy loss (EPL) among reproductive endocrinology and infertility specialists, with attention to mifepristone use. Design: Cross-sectional.
Zachary S. Anderson, M.D. +2 more
doaj +1 more source
A single-day treatment with mifepristone is sufficient to normalize chronic glucocorticoid induced suppression of hippocampal cell proliferation. [PDF]
PLoS ONE, 2012 BACKGROUND: Chronic stress or prolonged administration of glucocorticoids suppresses proliferation and/or survival of newborn cells in adult rat dentate gyrus.
Pu Hu +6 more
doaj +1 more source
Abortion—A brief description of the evolution of methods
Acta Obstetricia et Gynecologica Scandinavica, EarlyView.Termination of pregnancy is not a “modern” societal issue, but one that has been afforded to women, albeit with varying degrees of success, over many centuries. Methods have evolved which have increased the availability, effectiveness, and safety of abortion, while substantially reducing associated morbidity.
Laura Slade, Andrea Deussen, Jodie Dodd
wiley +1 more source
Clinical Endocrinology, EarlyView.ABSTRACT Objective Evaluate the effects of osilodrostat short‐ and long‐term treatment on health‐related quality of life (HRQoL) in Cushing's disease. Design LINC 3 and LINC 4 studies (pooled analysis). Patients 185 patients (mean baseline total scores: Cushing's Quality of Life [CushingQoL], 44.0; Beck Depression Inventory II [BDI‐II], 15.6; EuroQol ...
John Newell‐Price +6 more
wiley +1 more source
Mifepristone 5 mg versus 10 mg for emergency contraception: double-blind randomized clinical trial [PDF]
, 2015 Josep Lluis Carbonell,1 Ramon Garcia,2 Adriana Gonzalez,2 Andres Breto,2 Carlos Sanchez2 1Mediterranea Medica Clinic, Valencia, Spain; 2Eusebio Hernandez Gynecology and Obstetrics Teaching Hospital, Havana, Cuba Purpose: To estimate the efficacy and ...
Carbonell JL +4 more
core
Mifepristone With Buccal Misoprostol for Medical Abortion [PDF]
, 2015 ObjectiveTo summarize clinical outcomes and adverse effects of medical abortion regimens consisting of mifepristone followed by buccal misoprostol in pregnancies through 70 days of gestation.Data sourcesWe used PubMed, ClinicalTrials.gov, and reference ...
Creinin, Mitchell D, Chen, Melissa J
core +1 more source
Effects of mifepristone on adipocyte differentiation in mouse 3T3-L1 cells
Cellular & Molecular Biology LettersBackground Both glucocorticoid receptor and peroxisome proliferator-activated receptor-γ (PPARγ) play a critical role in adipocyte differentiation.
Takeshi Hashimoto, Katsuya Hirano
doaj +1 more source
Clinical Outcomes and Women's Experiences before and after the Introduction of Mifepristone into Second-Trimester Medical Abortion Services in South Africa. [PDF]
PLoS ONE, 2016 OBJECTIVE:To document clinical outcomes and women's experiences following the introduction of mifepristone into South African public sector second-trimester medical abortion services, and compare with historic cohorts receiving misoprostol-only.
Deborah Constant +6 more
doaj +1 more source